The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer

Appelbaum, Frederick R.

doi:10.3322/canjclin.46.3.142

Cited by 60 publications

(40 citation statements)

References 185 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 Oral mucositis (OM) is one of the most frequent adverse effects of allogenic or autologous hematopoietic SCT. It is caused by direct toxic injury to the mucosal epithelial cells.…”

Section: Introductionmentioning

confidence: 99%

The effect of oral management on the severity of oral mucositis during hematopoietic SCT

Yamagata

Arai

Sasaki

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

Oral mucositis (OM) is a frequent adverse effect of allogenic or autologous hematopoietic SCT. It results from direct toxic injury to the mucosal epithelial cells by the immunosuppressive regimen. Here, we compared the incidence and severity of OM between a group of 24 patients who received proper oral management during hematopoietic SCT and a group of 24 who did not. The oral management group received pre-hematopoietic SCT instruction on oral care and an oral examination in the clean room. Differences in the incidence and severity of OM between the two groups were examined statistically. OM was observed in 14 (58.3%) patients in the oral management group and 22 (91.6%) in the control group. The median of the OM score was 1 for the oral management group (range 0 to 3) and 2 for the control group (range 0 to 3). There was a significant difference in the OM score (Po0.05) and in the incidence of OM between the two groups (Po0.01). This study shows that oral management may decrease the occurrence of OM. Our results also suggest that it is important to include an oral management provider on the hematopoietic SCT team.

show abstract

“…1,2 Oral mucositis (OM) is one of the most frequent adverse effects of allogenic or autologous hematopoietic SCT. It is caused by direct toxic injury to the mucosal epithelial cells.…”

Section: Introductionmentioning

confidence: 99%

The effect of oral management on the severity of oral mucositis during hematopoietic SCT

Yamagata

Arai

Sasaki

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Their immunosuppressed status makes the patients more susceptible to infection, resulting in an increased risk of infectious complications, including the development of severe septicemia, that may be lifethreatening. 2,3 The oral cavity is a potential site of such infectious complications in patients receiving HSCT therapy, because it is an important port of entry for agents that can cause systemic infections. [4][5][6][7] To prevent these oral complications, pre-transplant comprehensive oral care has been incorporated into the preparatory steps for patients scheduled to receive HSCT therapy.…”

Section: Introductionmentioning

confidence: 99%

A prospective study to evaluate a new dental management protocol before hematopoietic stem cell transplantation

Yamagata

Onizawa

Yanagawa

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Multiple improvements in transplant technology, including the use of peripheral blood stem cells and minitransplants, are in investigational stages. Transplants carry the additional advantage of exerting a graft-versus-tumor (or graft-versus-leukemia) effect [26].…”

Section: Current Treatment Optionsmentioning

confidence: 99%

Targeting Hypomethylation of DNA to Achieve Cellular Differentiation in Myelodysplastic Syndromes (MDS)

Silverman

2001

The Oncologist

View full text Add to dashboard Cite

show abstract

The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer

Cited by 60 publications

References 185 publications

The effect of oral management on the severity of oral mucositis during hematopoietic SCT

The effect of oral management on the severity of oral mucositis during hematopoietic SCT

A prospective study to evaluate a new dental management protocol before hematopoietic stem cell transplantation

Targeting Hypomethylation of DNA to Achieve Cellular Differentiation in Myelodysplastic Syndromes (MDS)

Contact Info

Product

Resources

About